ATRIUM
Enrolling By Invitation
18-99 years
All
Phase
3
30 participants needed
1 Location
Brief description of study
The primary aim of this trial is to test in a randomized double-blind placebo-controlled study whether abatacept, administered concurrently with corticosteroids, is associated with a reduction in major cardiovascular events among participants with recently diagnosed ICI myocarditis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Immune Checkpoint Inhibitor related Myocarditis
-
Age: Between 18 Years - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 852258
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
